Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS

被引:47
|
作者
Sgagias, MK
Wagner, KU
Hamik, B
Stoeger, S
Spieker, R
Huber, LJ
Chodosh, LA
Cowan, KH
机构
[1] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA
[2] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
关键词
Bcra1-deficiency; DNA-damage and repair; breast cancer; CDDP; MMS;
D O I
10.4161/cc.3.11.1211
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In this report we describe the isolation of an isogenic pair of Brca1(++) and Brca1(-/-) murine mammary epithelial cells (MMECs). These cells were isolated from Brca1 conditional knock-out mice which contained loxP sites flanking exon 11 of the Brca1 gene (Brca1(f1/f1)) and then immortalized by infection with HPV-16E6 retrovirus to degrade p53 protein. Brca1-/- MMECs were generated by deletion of exon 11 following transduction of Brca1(f1/f1) MMECs with a retroviral vector expressing Cre recombinase. Brca1-deficiency rendered MMECs sensitive to cis-platinum (II) diamine dichloride ( CDDP) and methylmethane sulfonate (MMS). The Brca1(+/+) and Brca1(-/-) MMECs is the only known pair of isogenic mammary epithelial cell lines. The understanding of the mechanisms of the CDDP sensitivity of the BRCA1-deficient mammary epithelial cells would be very important in understanding how BRCA1-deficiency plays a role in tissue specific breast cancer chemotherapy. These studies support the role of BRCA1 in the CDDP-induced and MMS-induced DNA damage and repair by p53-independent pathways.
引用
收藏
页码:1451 / 1456
页数:6
相关论文
共 50 条
  • [41] Immune response and replication stress cause differences in radiosensitivity in BRCA1-deficient breast cancer cells
    Classen, Sandra
    Gehre, Simon
    Ruckert, Michael
    Pospiech, Helmut
    Rothkamm, Kai
    Petersen, Cordula
    Gaipl, Udo S.
    Borgmann, Kerstin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S36 - S36
  • [42] Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage
    Sau, Andrea
    Lau, Rosanna
    Cabrita, Miguel A.
    Nolan, Emma
    Crooks, Peter A.
    Visvader, Jane E.
    Pratt, M. A. Christine
    CELL STEM CELL, 2016, 19 (01) : 52 - 65
  • [43] Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
    Pajic, Marina
    Blatter, Sohvi
    Guyader, Charlotte
    Gonggrijp, Maaike
    Kersbergen, Ariena
    Kucukosmanoglu, Asli
    Sol, Wendy
    Drost, Rinske
    Jonkers, Jos
    Borst, Piet
    Rottenberg, Sven
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 7020 - 7033
  • [44] 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
    Bunting, Samuel F.
    Callen, Elsa
    Wong, Nancy
    Chen, Hua-Tang
    Polato, Federica
    Gunn, Amanda
    Bothmer, Anne
    Feldhahn, Niklas
    Fernandez-Capetillo, Oscar
    Cao, Liu
    Xu, Xiaoling
    Deng, Chu-Xia
    Finkel, Toren
    Nussenzweig, Michel
    Stark, Jeremy M.
    Nussenzweig, Andre
    CELL, 2010, 141 (02) : 243 - 254
  • [45] DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
    He, Yizhou Joseph
    Meghani, Khyati
    Caron, Marie-Christine
    Yang, Chunyu
    Ronato, Daryl A.
    Bian, Jie
    Sharma, Anchal
    Moore, Jessica
    Niraj, Joshi
    Detappe, Alexandre
    Doench, John G.
    Legube, Gaelle
    Root, David E.
    D'Andrea, Alan D.
    Drane, Pascal
    De, Subhajyoti
    Konstantinopoulos, Panagiotis A.
    Masson, Jean-Yves
    Chowdhury, Dipanjan
    NATURE, 2018, 563 (7732) : 522 - +
  • [46] DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
    Yizhou Joseph He
    Khyati Meghani
    Marie-Christine Caron
    Chunyu Yang
    Daryl A. Ronato
    Jie Bian
    Anchal Sharma
    Jessica Moore
    Joshi Niraj
    Alexandre Detappe
    John G. Doench
    Gaelle Legube
    David E. Root
    Alan D. D’Andrea
    Pascal Drané
    Subhajyoti De
    Panagiotis A. Konstantinopoulos
    Jean-Yves Masson
    Dipanjan Chowdhury
    Nature, 2018, 563 : 522 - 526
  • [47] Brca1-deficient pancreatic ductal adenocarcinoma cells are hyper-sensitive to DNA-damaging agents
    Hirsch, S.
    Shakya, R.
    Szabolcs, M.
    Hartmann, J-T
    Ludwig, T.
    ONKOLOGIE, 2011, 34 : 57 - 57
  • [48] Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells
    Garcia, Iris A.
    Florencia Pansa, Maria
    Del Valle Pacciaroni, Adriana
    Garcia, Manuela E.
    Laura Gonzalez, Maria
    Carlos Oberti, Juan
    Luis Bocco, Jose
    Cecilia Carpinella, Maria
    Barboza, Gloria E.
    Nicotra, Viviana E.
    Soria, Gaston
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [49] Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
    Farkkila, Anniina
    Rodriguez, Alfredo
    Oikkonen, Jaana
    Gulhan, Doga C.
    Huy Nguyen
    Dominguez, Julieta
    Ramos, Sandra
    Mills, Caitlin E.
    Perez-Villatoro, Fernando
    Lazaro, Jean-Bernard
    Zhou, Jia
    Clairmont, Connor S.
    Moreau, Lisa A.
    Park, Peter J.
    Sorger, Peter K.
    Hautaniemi, Sampsa
    Frias, Sara
    D'Andrea, Alan D.
    CANCER RESEARCH, 2021, 81 (10) : 2774 - 2787
  • [50] BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
    Puppe, Julian
    Drost, Rinske
    Liu, Xiaoling
    Joosse, Simon A.
    Evers, Bastiaan
    Cornelissen-Steijger, Paulien
    Nederlof, Petra
    Yu, Qiang
    Jonkers, Jos
    van Lohuizen, Maarten
    Pietersen, Alexandra M.
    BREAST CANCER RESEARCH, 2009, 11 (04)